Study of Serum Level of Advanced Glycated Endproducts and Development of Coronary Atherosclerosis in Patients Undergoing Coronary Angiogram
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 10,000
- 试验地点
- 1
- 主要终点
- MACE
研究概览
简要总结
Blood sample is prospectively taken from consecutive patients underwent coronary angiogram in our center, after getting informed consent from the patients. Serum level of advanced glycation end products (AGEs) was measured and the clinical features of patients (including angiographic results) were entered into our database. Clinical follow-up was performed for all patients, and the relationship between AGEs and paitents' outcome were analyzed. Further intervention will be adjusted according to the results,including clinical and basic research in lab.
详细描述
Serum levels of HMGB1, HMGB2, ADAM10, etc. will be measured in lab and animal studies will be designed to intervene the adverse interaction between abnormal serum concentration of AGEs, etc. and worse clinical results.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 90 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •patients underwent coronary angiogram for suspected coronary artery disease and potential percutaneous coronary intervention
排除标准
- •patients underwent coronary angiogram for other reasons, including pre-surgery examination
- •patients with severe co-morbidity, and life expectancy less than one-year
结局指标
主要结局
MACE
时间窗: 5-year
including death, occurrence of myocardial infarction, and coronary revascularization
次要结局
- progression in coronary atherosclerosis(5-year)
研究者
Zhang Qi, MD
Director, Cardiac Catheterization Lab
Shanghai Jiao Tong University School of Medicine